Contact
Please use this form to send email to PR contact of this press release:
Multi-Antigen CAR T Technology, Cell Therapy and In Vitro Diagnostics with Multiple Cancer Types: Coeptis: NASDAQ: COEP
TO:
Coeptis Therapeutics Holdings, Inc.
Dave Mehalick, President and CEO
+1 724-934-6467